Dhampur Bio Organics has completed the acquisition of a 74% stake in DBION Private Limited, formerly known as Sonitron Chemicals Private Limited, for a total consideration of ₹74,000. This strategic move, executed on July 09, 2026, transforms DBION Private Limited into a subsidiary of Dhampur Bio Organics and establishes it as a joint venture company under an agreement with Orgonew Private Limited.

Transaction Details

The acquisition involved the purchase of 7,400 equity shares at a rate of ₹10 each. This transaction represents 74% of the paid-up equity share capital of DBION Private Limited. The deal was structured in accordance with the Joint Venture Agreement entered into with Orgonew Private Limited.

Strategic Implications

With this acquisition, Dhampur Bio Organics secures a controlling interest in DBION Private Limited. The entity will now function as a subsidiary and a joint venture, allowing the acquirer to exercise significant influence over its operations and strategic direction. The completion follows prior board approvals on April 20, 2026, and May 30, 2026.

Dhampur Bio Organics Limited has completed the dispatch of the notice for its 6th Annual General Meeting and the Annual Report for the financial year 2025-26. The meeting is scheduled for Friday, July 24, 2026, at 04:00 P.M. IST via video conferencing. The company has fixed Friday, July 17, 2026, as the record date to determine shareholder eligibility for the final dividend, subject to approval at the AGM.

Pursuant to Regulation 30 read with Schedule III, Regulation 44 and Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, the company submitted copies of the publication in Business Standard dated July 2, 2026, to the stock exchanges. The publication confirms the dispatch of the notice and details regarding e-voting and the record date.

The Board of Directors has recommended a final dividend of 15%, amounting to ₹1.50 per equity share, for the financial year ended March 31, 2026. The remote e-voting period will commence on Monday, July 20, 2026, at 09:00 A.M. and conclude on Thursday, July 23, 2026, at 05:00 P.M. Mr. Saket Sharma (FCS-4229), Partner, M/s GSK & Associates, has been appointed as the Scrutinizer for the voting process.

Key Resolutions

Shareholders will consider the re-appointment of M/s Mittal Gupta & Company as Statutory Auditors for a second term of five years, commencing from the conclusion of this AGM until the 11th AGM in the financial year 2031-2032. A special resolution proposes the re-designation of Mr. Gautam Goel (DIN: 00076326) from Managing Director and Chief Executive Officer to Executive Chairman and Chief Executive Officer, effective May 31, 2026.

Remuneration and Appointments

The AGM will address amendments to the Articles of Association to allow the appointment of a Chief Executive Officer and/or Managing Director as Chairman. Resolutions include the revision of remuneration for Ms. Maayashree Goel and Ms. Meerashree Goel, both appointed as General Manager-Management Team. Their basic salaries will increase to ₹5,00,000 per month effective August 1, 2026. The company also seeks approval to pay a commission of ₹12,00,000 each to all Non-Executive Directors for the financial year 2025-26.

Financial and Administrative Approvals

Members will ratify the remuneration of ₹1,80,000 per annum plus applicable taxes for Mr. S.R. Kapur, Cost Accountant, for the financial year 2026-27. The electronic copies of the Notice of AGM and Annual Report have been sent to members whose e-mail IDs are registered with the Company or Depository Participant(s).